Creon 10

Medical Editor: John P. Cunha, DO, FACOEP Last updated on RxList: 2/8/2022

Drug Summary

What Is Creon 10?

Creon 10 Minimicrospheres (pancrelipase) Delayed-release Capsules is a combination of three enzymes (proteins): lipase, protease, and amylase, and is used to replace these enzymes when the body does not have enough of its own. Certain medical conditions can cause this lack of enzymes, including cystic fibrosis, chronic inflammation of the pancreas, or blockage of the pancreatic ducts. Creon 10 Minimicrospheres may also be used following surgical removal of the pancreas.

What Are Side Effects of Creon 10?

Common side effects of Creon 10 Minimicrospheres include:

  •  diarrhea
  • constipation
  • stomach pain or upset
  • abdominal cramps
  • dizziness
  • nausea
  • vomiting
  • bloating or gas
  • greasy stools
  • rectal irritation
  • headache
  • cough, or
  • weight loss

Dosage for Creon 10

The usual starting dosage for adults and children over age 6 is one to two Creon 10 Capsules per meal or snack. The usual starting dosage for children under 6 years is up to one Creon 10 Capsule per meal or snack.

What Drugs, Substances, or Supplements Interact with Creon 10?

Creon 10 may interact with other drugs. Tell your doctor all medications and supplements you use.

Creon 10 During Pregnancy and Breastfeeding

During pregnancy, Creon 10 should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Creon 10 Minimicrospheres (pancrelipase) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

Drug Description


CREON® 10 Capsules are orally administered and contain pancrelipase (lipase 10,000 USP Units, protease 37,500 USP Units, and amylase 33,200 USP Units per capsule) which is of porcine pancreatic origin. Each CREON 10 (pancrelipase delayed-released capsules) Capsule is filled with 249 mg of delayed-release MINIMICROSPHERES®.

Inactive ingredients include dibutyl phthalate, dimethicone, hydroxypropylmethylcellulose phthalate, light mineral oil and polyethylene glycol. The capsule shells contain black iron oxide, gelatin, red iron oxide, titanium dioxide, and yellow iron oxide. The capsule imprinting ink contains dimethicone, 2-ethoxyethanol, shellac, soya lecithin, and titanium dioxide.

Indications & Dosage


CREON 10 (pancrelipase delayed-released capsules) Capsules are indicated for patients with pancreatic exocrine insufficiency as is often associated with:


Clinical experience should dictate initial starting dose. Doses should be taken during meals or snacks, not before or after. Do not take without food.

Adults and Children Over 6 Years Old

Usual initial starting dosage is one to two CREON 10 (pancrelipase delayed-released capsules) Capsules per meal or snack.

Children Under 6 Years Old

Usual initial starting dosage is up to one CREON 10 (pancrelipase delayed-released capsules) Capsule per meal or snack.

For cystic fibrosis patients, typical doses are 1,500 - 3,000 USP lipase units/kg/meal. Dosage should be adjusted according to the severity of the disease, control of steatorrhea and maintenance of good nutritional status. Doses in excess of 6,000 USP lipase units/kg/meal are not recommended.

Dose increases, if required, should occur with careful monitoring of body weight and stool fat content. When changing strengths of pancreatic enzyme products, care should be taken to maintain equivalent lipase units for each divided dosage.

It is important to ensure adequate hydration of patients at all times while taking pancreatic enzymes.

Where swallowing of capsules is difficult, the capsules may be carefully opened and the MINIMICROSPHERES added to a small amount of soft food, with a pH less than 5.5. The soft food should be swallowed immediately without chewing and followed with a glass of water or juice to insure swallowing.


CREON 10 MINIMICROSPHERES (Pancrelipase Delayed-release Capsules, USP) are available in a two-piece gelatin capsule (brown opaque top half, natural transparent bottom half) imprinted in white with "SOLVAY" and "1210". Each capsule contains tan-colored delayed-release MINIMICROSPHERES of pancrelipase supplied in bottles of:

100.......NDC 0032-1210-01
250.......NDC 0032-1210-07

CREON 10 (pancrelipase delayed-released capsules) Capsules must be stored at 25ºC (77ºF); excursions permitted to 15º-30ºC (59º- 86ºF). [See USP Controlled Room Temperature.] PROTECT FROM MOISTURE. DO NOT REFRIGERATE. Dispense in tight, light-resistant containers. For human consumption only.

Manufactured By: Solvay Pharmaceuticals GmbH, Hannover, Germany. Marketed by: Solvay Pharmaceuticals, Inc. Marietta, GA 30062. Rev Feb 2006. FDA Rev date: n/a

Side Effects & Drug Interactions


The most frequently reported adverse reactions to pancreatic enzyme-containing products are gastrointestinal in nature which may include nausea, vomiting, bloating, cramping, constipation or diarrhea. Less frequently, allergic-type reactions have also been observed. Very high doses of pancreatin have been associated with hyperuricosuria and hyperuricemia.


No information provided.



Should symptoms of hypersensitivity appear, discontinue medication and initiate symptomatic and supportive therapy if necessary.

Strictures in the ileo-cecal region and/or ascending colon have been reported in cystic fibrosis patients treated with high doses of high-potency pancreatic enzyme supplements containing 20,000 or greater USP units of lipase per capsule. The underlying mechanism is unknown, but

caution should be exercised when doses in excess of 6,000 USP units lipase per kg per meal fail to resolve symptoms, especially in patients with a history of intestinal complications such as meconium ileus equivalent, short bowel syndrome, surgery or Crohn's disease. If symptoms suggestive of gastrointestinal obstruction occur, the possibility of bowel stricture should be investigated including evaluation of pancreatic enzyme therapy.



CREON 10 (pancrelipase delayed-released capsules) Capsules MINIMICROSPHERES SHOULD NOT BE CRUSHED OR CHEWED or placed on foods having a pH greater than 5.5. These can dissolve the protective enteric coating resulting in early release of enzymes, irritation of oral mucosa, and/or loss of enzyme activity.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential.

Pregnancy, Category C

Animal reproduction studies have not been conducted with pancrelipase. It is also not known whether pancrelipase can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. CREON 10 (pancrelipase delayed-released capsules) Capsules should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when CREON 10 (pancrelipase delayed-released capsules) Capsules are administered to a nursing mother.

Overdose & Contraindications


No information provided.


CREON 10 (pancrelipase delayed-released capsules) Capsules are contraindicated in the early stages of acute pancreatitis or in patients who are known to be hypersensitive to pork protein.

Clinical Pharmacology


The pancreatic enzymes in CREON 10 (pancrelipase delayed-released capsules) Capsules are enteric-coated to resist gastric destruction or inactivation. The pancreatic enzymes catalyze the hydrolysis of fats to glycerol and fatty acids, protein into proteoses and derived substances and starch into dextrins and short chain sugars.

Medication Guide


CREON 10 (pancrelipase delayed-released capsules) Capsules are a pancreatic enzyme product prescribed to promote improved digestion of foods, especially fat. The prescribed dosage should be taken with each meal and snack or as directed by the physician. The capsules can be swallowed whole, or the contents poured on soft, bland food. Care should be taken to avoid chewing or crushing of the capsule contents, which can result in early release of enzymes, irritation of oral mucosa, and/or loss of enzyme activity. Patients should maintain adequate fluid intake. The prescribed dose range should not be exceeded without calling your doctor.

The most common adverse reactions involve the stomach and intestine including diarrhea, nausea, vomiting, bloating, constipation, stomach cramps or pain. If these symptoms are persistent, contact your doctor.

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.